Sobi publishes the report for the fourth quarter and full-year 2018
Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces the results for the fourth quarter and full-year 2018. Total revenues grew 37 per cent compared with Q4 2017 (29 per cent at constant exchange rates (CER)) and amounted to SEK 2,571 M. EBITA was SEK 916 M, an increase of 48 per cent for the quarter, and gross margin amounted to 74 per cent. Highlights · Total revenues of SEK 2,571 M (1,875) in Q4 and SEK 9,139 M (6,511) for the full year · 37 per cent sales growth in Q4 compared with Q4 2017 (29 per cent at (CER)) · EBITA1increased 48 per cent